Pharmacokinetics of meropenem in experimentally burned rats. 1993

T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
Department of Plastic and Reconstructive Surgery, School of Medicine, Hokkaido University, Sapporo, Japan.

The pharmacokinetics of meropenem were investigated to examine its penetration into the skin of third degree burned rats. The rats were divided into two groups. One group acted as the control, and the other group had third degree burns induced by immersing their backs into 80 degrees C water for 20 seconds. The rats in each group were given 20 mg/kg of body weight of meropenem intravenously by one bolus injection seven days after burn inducement or depilation. In the non-burned control group, the maximum concentrations of meropenem in the serum and skin of 6.03 micrograms/ml and 0.12 microgram/g were respectively obtained 15 minutes after the injection and decreased very rapidly thereafter. In the burned rats, the maximum concentrations of meropenem in the serum, skin (eschar), and exudate fluid of 7.07 micrograms/ml, 1.44 micrograms/g and 5.99 micrograms/ml were respectively obtained 15 minutes after the injection and decreased very slowly. The penetration of meropenem into the burned skin was higher than that into the normal skin. These results suggest that meropenem is a very useful antibiotic in the treatment of burn infection.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D005122 Exudates and Transudates Exudates are fluids, CELLS, or other cellular substances that are slowly discharged from BLOOD VESSELS usually from inflamed tissues. Transudates are fluids that pass through a membrane or squeeze through tissue or into the EXTRACELLULAR SPACE of TISSUES. Transudates are thin and watery and contain few cells or PROTEINS. Transudates,Exudates,Transudates and Exudates,Exudate,Transudate
D000077731 Meropenem A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid,Merrem,Penem,Ronem,SM 7338,SM-7338,SM7338
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014946 Wound Infection Invasion of a wound by pathogenic microorganisms. Infection, Wound,Infections, Wound,Wound Infections
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
January 1969, Scandinavian journal of plastic and reconstructive surgery,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
April 1980, The Journal of pharmacology and experimental therapeutics,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
April 1995, Clinical pharmacokinetics,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
January 1995, Scandinavian journal of infectious diseases. Supplementum,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
September 2009, Antimicrobial agents and chemotherapy,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
June 1967, Virchows Archiv fur pathologische Anatomie und Physiologie und fur klinische Medizin,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
June 2001, Therapeutic drug monitoring,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
September 1989, The Journal of antimicrobial chemotherapy,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
January 2017, Pharmacognosy magazine,
T Yoshida, and K Homma, and K Azami, and T Sugihara, and T Ohura
January 1964, Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove,
Copied contents to your clipboard!